Cantargia AB is a clinical-stage biotech company based in Lund focused on developing antibody-based therapies targeting the IL1RAP protein in cancer treatment. Founded in 2010 as a spin-off from Lund University, Cantargia is advancing nadunolimab (CAN04) in clinical trials for pancreatic and lung cancers. Listed on Nasdaq Stockholm, the company represents Lund's strength in translational oncology research.
cantargia.comPart of: Skåne Startup map